Investigating tirzepatide's role in weight loss and metabolic health

Investigating tirzepatide's role in weight loss and metabolic health

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide—a drug known as Zepbound—on weight loss with respect to energy expenditure, fat oxidation and calorie intake.

Eli Lilly sues companies selling alternative versions of its weight loss drug

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of its drug Zepbound.

Eli Lilly is stepping up its fight against copycat weight-loss drugs

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.Read more...

Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.

Eli Lilly opens a new legal front in its battle against compounded GLP-1s

Eli Lilly sued four telehealth firms and their affiliates, but it is adopting a new legal strategy in its fight against compounded GLP-1s.

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.